Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer

Urologic Oncology Seminars and Original Investigations 2026

View at publisher
Authors: Shugo Yajima, Soichiro Yoshida, Wei Chen, Hiroshi Fukushima, Hajime Tanaka, Hiroyuki Sato, Akihiro Hirakawa, Hitoshi Masuda, Yasuhisa Fujii
DOI: 10.1016/j.urolonc.2026.05.019
Cited by: 1
References: 8

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Prostate Cancer Diagnosis and Treatment

Publication details

Journal / source
Urologic Oncology Seminars and Original Investigations
Publisher
Elsevier BV
Volume
44
Issue
8
Pages
120–126
Publication date
5 June 2026
Language
EN